1. Burns JJ, Yü TF, Ritterbrand A, Perel JM, Gutman AB, Brodie BB (1957) A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue G-25671. J Pharmacol Exp Ther 119:418–426
2. Kuzell WC, Glover RP, Gibbs JO, Blau RA (1964) Effect of sulfinpyrazone on serum uric acid in gout. A long-term study. Geriatrics 19:894–909
3. Smythe HA, Ogryzlo MA, Murphy EA, Mustard JF (1965) The effect of sulfinpyrazone on platelet economy and blood coagulation in man. Can Med Assoc J 92:818–821
4. Mustard JF, Rowsell HC, Smythe HA, Senyi A, Murphy EA (1967) The effect of sulfinpyrazone on plaetelet economy and thrombus formation in rabbits. Blood 29:859–866
5. Blakely JA, Gent M (1975) Platelets, drugs and longevity in a geriatric population. In: Hirsh J, Cade JF, Gallus AS, Schönbaum E (eds) Platelets, drugs and thrombosis. Karger, Basel, pp 284–291